The Company Had The First-ever Cannabis Product Allowed For Import Into Brazil And Its Products Are Currently Subsidized By The Brazilian Government, Under Their Health Care System, For All Three Medical Indications Listed Above.

Saul Garza has recently mentioned that he is currently enrolling patients for a study on the effects of CBD on autism. This study comes after Dr. Garza concluded a research study on Lennox-Gastaut epilepsy in Mexico withfavorable results for the botanical CBD version that is allowed into Mexico(HempMeds RSHO-X). These results are set to be published in the near future andformally presented at the International Epilepsy Congress in Barcelona, Spain, Sept. 2-6, 2017. About HempMeds Brasil HempMeds Brasil currently has three cannabis products approved for importation into Brazil as a prescription medication for Epilepsy, Parkinson’s and Chronic Pain. The company had the first-ever cannabis product allowed for import into Brazil and its products are currently subsidized by the Brazilian government, under their health care system, for all three medical indications listed above. HempMeds Brasil is working on Medical marijuana additional approvals for multiple indications. About Medical Marijuana, Inc. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com .

To read more visit http://www.marketwatch.com/story/autism-approval-medical-marijuana-inc-subsidiary-hempmeds-brasil-receives-brazilian-government-permission-for-import-of-flagship-product-rshotm-2017-02-28

Share This Post

Recent Articles

Leave a Reply